Atherotech Adds Two Members to the Board of Directors

BIRMINGHAM, AL— May 8, 2007 — Atherotech, Inc., a pioneer in cardiodiagnostic cholesterol testing technology renowned for its VAP Cholesterol Test, today announced the additions of Laura G. King and Kenneth M. Roe as independent members to its board of directors. Most recently, King served as President and CEO of the $1.2 billion GE Healthcare Interventional Cardiology Business. Roe, currently retired, last served as Regional Vice President and Operations Leader for Quest Diagnostics Incorporated, where he oversaw lab operations exceeding $1 billion in annual revenue.

“We are very pleased to welcome Laura and Ken to Atherotech's board,” said David Schreiber, President and CEO of Atherotech. “They both bring extensive healthcare industry and leadership experience, and we are confident that their broad based insight will help accelerate the Company's growth rate and utilization of the VAP test within the Cholesterol testing market.”

“It is a pleasure to welcome such high caliber executives to Atherotech's board,” said Kneeland Youngblood, MD, chairman of Atherotech's board and longtime investor in the company through Pharos Capital Group. “The ability to attract top quality board members – such as Laura and Ken – demonstrates the attractiveness of Atherotech's leading edge technology. We look forward to tapping Laura and Ken's vast expertise as we seek to propel Atherotech's growth initiatives to the next level.”

As President and CEO of GE Healthcare Interventional Business, King, 43, focused on minimally invasive procedures in Cardiology, Interventional Radiology and Surgery. She began her career with GE Healthcare in 1995 and served as a General Manager in the U.S. and internationally. King started her career at GE in 1985, working in audit and business development. From 1992 to 1995, she was CIO of GE Motors and CFO of GE Consumer and ECM Motors. King is also a recipient of the Jack Welch Outstanding Women Leaders Award, which she received in 2000. She earned a B.A. in Economics from the University of California at Davis.

Roe, 55, has an extensive history in diagnostics and laboratory management. From 1997 to 2004, he served as Regional Vice President and Operations Leader for Quest Diagnostics Incorporated, responsible primarily for the Central United States. During his tenure at Quest, he oversaw operations of approximately one-third of the company's revenue, and he also helped lead Quest's integration of SmithKline Beecham Labs, following their merger in 2000.

Executive bios may be viewed on Atherotech's website at www.atherotech.com.